Apple 2003 Annual Report Download - page 106

Download and view the complete annual report

Please find page 106 of the 2003 Apple annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 164

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164

8.0 CONFIDENTIAL INFORMATION
8.1 In the event IBM or Apple wishes to disclose specific confidential information to the other in connection with IBM furnishing
Products and/or Services hereunder, such information shall be disclosed only pursuant to the terms and conditions of the Apple Computer, Inc.
Confidentiality Agreement (Mutual), Agreement No. X1329, as amended, signed by IBM and Apple with an effective date of April 1, 1999, the
current version of which, and all currently effective Amendments to the same, are attached hereto as Exhibit 6, or pursuant to the terms and
conditions of another comparable confidential disclosure agreement. The parties agree to treat the terms and conditions of this Agreement as
confidential information.
9.0 LICENSE
9.1 No license, immunity or other right is granted herein to any Authorized Purchaser or Designee whether directly or by implication,
estoppel or otherwise, with respect to any patent, trademark, copyright, mask work, trade secret, utility, model, or know-how, or other
intellectual property right of IBM. Nothing herein shall abrogate any rights that may arise by operation of the patent exhaustion doctrine.
10.0 TRADEMARK
10.1 Nothing in this Agreement grants either party any rights to use the other party’s trademarks or trade names, directly or indirectly, in
connection with any product, service, promotion, or to make any publication or publicity without prior written approval of the other
party or trademark or trade name owner.
11.0 INTELLECTUAL PROPERTY AND INDEMNIFICATION
11.1 Neither party is required by this Agreement to knowingly infringe any valid patent or other intellectual property of a third party. If
either party has reason to believe that any Item, Product or portion thereof infringes such an intellectual property right, it will promptly escalate
its concern to the executive of the other party designated for such escalations pursuant to Section 21.2, and the parties will work together to
make necessary changes or provide substitute Items or Products so as to avoid infringement. IBM may stop shipments of all such Products
without liability for failure to deliver a Product under this Agreement for up to [**] while IBM and Apple analyze the potential infringement
and discuss whether shipments should resume. If a Product becomes or is likely to become the subject of a claim covered by Section 11.2,
below, IBM will, at its own expense: (i) obtain the rights and licenses necessary to permit Authorized Purchasers and Designees to continue to
use and sell the Products consistent with this Agreement;
[**] = information redacted pursuant to a confidential treatment request. Such omitted information has been filed separately with the Securities
and Exchange Commission.